New evidence suggests the efficacy of the probiotic LPLDL in reducing LDL cholesterol levels in hypercholesterolemic adults, according to a study published in Journal of Functional Foods. LPLDL is a strain of Lactobacillus plantarum, branded by ProBiotix.
The parallel, double-blind, placebo-controlled, randomized pilot study investigated LPLDL in 16 hypercholesterolemic adults. Participants were given 4×109 CFU LPLDL or a placebo once daily for six weeks, followed by a three-week washout period. Fasting blood samples were collected for blood lipid, liver function, and vitamin D analysis.
After 6 weeks of supplementation, statistically significant reductions were noted in total cholesterol by an average of 34.6%, with an average reduction of LDL cholesterol of 28.4%, as compared to the placebo. No changes were observed in liver function biomarkers or vitamin D.
Stephen O’Hara, CEO at OptiBiotix, commented in a press release: “The results of this study are remarkable and firmly establish LPLDL as the probiotic for heart health. Our previous human intervention studies have highlighted LPLDL as an excellent candidate to reduce cholesterol across different patient groups and countries. Now, with the statistically significant results of our latest study, both partners and consumers can rest assured they are using a science-backed probiotic that not only reduces total cholesterol, but multiple risk factors associated with CHD. For the industry, this is a significant step forward for a probiotic that can truly make a difference, demonstrating that LPLDL champions scientific evidence to deliver impressive results.”